Datos del Documento


Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/14777
Registro de Metadatos Completo
Campo Dublin Core Valor Idioma
dc.contributor.authorPena Larrea, Lorena-
dc.contributor.authorde Blas Rodríguez, Manuela-
dc.contributor.authorNaves Díaz, Manuel-
dc.contributor.authorGómez Alonso, Carlos-
dc.date.accessioned2024-04-09T13:15:38Z-
dc.date.available2024-04-09T13:15:38Z-
dc.date.issued2023-
dc.identifier.citation- Larrea, LP; Rodríguez, MD; Díaz, MN; Alonso, CG. Las células senescentes como factores patogénicos y posibles dianas terapéuticas en osteoporosis. Rev. Osteoporos. Metab. Min. 2023. 15. (3). DOI: 10.20960/RevOsteoporosMetabMiner.00013.es_ES
dc.identifier.issn2173-2345-
dc.identifier.urihttps://ria.asturias.es/RIA/handle/123456789/14777-
dc.description.abstractCellular senescence is a process induced by various types of stress that irreversibly cause cell cycle arrest and changes to the characteristics and functionality of cells, as well as the acquisition of a secretory phenotype that generates a pro-in-flammatory environment. While, in certain contexts, it is beneficial for tissues and promotes organism development, senes-cence is a cellular fate implicated in the process of aging and age-related degenerative conditions. Senolytics are drugs that specifically eliminate senescent cells, and senomorphics are drugs that suppress their senescence-associated secretory phenotype (SASP) without inducing cell death. Therefore, therapeutic strategies targeting senescent cells (senolytics and senomorphics) as an underlying mechanism of aging emerge as an alternative with great potential to fight age-related diseases as a whole rather than individually. One of these conditions is osteoporosis where it has been experimentally described that drugs such as zoledronic acid have effects on preosteoblasts and act on senescent cells extending survival and opening up the possibility of treating age-related diseases with drugs already used in practice, which may have effects beyond the bone itself and increase overall survival. In this study, a review will be conducted in this rapidly growing field in recent years of undeniable translational interest.es_ES
dc.description.sponsorshipInstituto de Investigación Sanitaria del Principado de Asturias (ISPA)es_ES
dc.language.isoeses_ES
dc.publisherRevista de Osteoporosis y Metabolismo Minerales_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectSenescenciaes_ES
dc.subjectOsteoporosises_ES
dc.subjectSenolíticoses_ES
dc.subjectSenomórficoses_ES
dc.subjectHuesoes_ES
dc.subjectFragilidades_ES
dc.subjectFenotipo secretor asociado a senescencia (SASP)es_ES
dc.titleLas células senescentes como factores patogénicos y posibles dianas terapéuticas en osteoporosises_ES
dc.typeArtículoes_ES
dc.typeOtroses_ES
Aparece en las colecciones: Sanidad

Archivos en este documento:
Fichero Descripción Tamaño Formato  
MA-00013-01.pdf1.6 MBAdobe PDFVer/Abrir
Mostrar el registro Básico


Ver estadísticas del documento


Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons